Scienture (NASDAQ:SCNX) Posts Earnings Results, Misses Estimates By $1.48 EPS

Scienture (NASDAQ:SCNX) announced its quarterly earnings results on Monday. The company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($0.28) by ($1.48), FiscalAI reports. The firm had revenue of ($0.17) million during the quarter, compared to analysts’ expectations of $0.49 million.

Scienture Trading Up 18.3%

SCNX opened at $0.29 on Wednesday. The firm has a market cap of $11.58 million, a price-to-earnings ratio of -0.10 and a beta of 3.01. Scienture has a 12 month low of $0.24 and a 12 month high of $2.60. The stock has a fifty day moving average price of $0.44 and a 200-day moving average price of $0.61.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Scienture to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Scienture in a report on Friday. Finally, Maxim Group began coverage on shares of Scienture in a research report on Tuesday, February 24th. They issued a “buy” rating and a $1.50 price target for the company. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $1.50.

Hedge Funds Weigh In On Scienture

An institutional investor recently bought a new position in Scienture stock. Virtu Financial LLC bought a new position in Scienture Holdings, Inc. (NASDAQ:SCNX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned approximately 0.22% of Scienture as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 5.68% of the company’s stock.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.